8-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulene | 748804-96-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 8-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulene
• 英文别名: 8-Methyl-1-(1-pyridin-2-ylpiperidin-4-yl)-4,6-dihydro-[1,2,4]triazolo[4,3-a][4,1]benzoxazepine
• CAS: 748804-96-8
• 化学式: C₂₁H₂₃N₅O
• 分子量: 361.447
• InChiKey: CLDGOUPTBINSFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  56.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-methyl-2-[5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-ylmethoxymethyl]-phenylamine 在 对甲苯磺酸 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 18.0h， 生成 8-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulene
  参考文献：
  名称：

  Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability

  摘要：

  The V1a receptor has emerged as an attractive target for a range of indications including Raynaud's disease and dysmenorrhoea. As part of an effort to discover a new class of orally active V1a antagonist, we optimised a highly lipophilic, metabolically unstable lead into a range of potent, selective and metabolically stable V1a antagonists. In this communication, we demonstrate the series-dependent effect of limiting the number of rotatable bonds in order to decrease Cytochrome P450-mediated metabolism. This effort culminated in the discovery of PF-184563, a novel, selective V1a antagonist with excellent in vitro and in vivo properties. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.038

文献信息

• Treatment of male sexual dysfunction
  申请人：Wayman Peter Christopher

  公开号：US20050026810A1

  公开（公告）日：2005-02-03

  The present invention relates the use of antagonists of vasopressin V1a receptors for the treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation. The present invention also relates to a method of treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation. The present invention also relates to assays to screen for compounds useful in the treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation, by screening for compounds which are V1a receptor antagonists.

  本发明涉及使用抗利尿激素V1a受体拮抗剂治疗男性性功能障碍，特别是射精障碍，如早泄或快速射精。本发明还涉及一种治疗男性性功能障碍的方法，特别是射精障碍，如早泄或快速射精。本发明还涉及筛选有用于治疗男性性功能障碍的化合物的测定方法，特别是通过筛选V1a受体拮抗剂化合物进行筛选，以治疗射精障碍，如早泄或快速射精。
• Triazole compounds useful in therapy
  申请人：Bryans Stephen Justin

  公开号：US20060194794A1

  公开（公告）日：2006-08-31

  A compound of formula (I), or a pharmaceutically acceptable derivative, wherein A, B, V, W, X, Y, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof.

  一种化合物的公式（I），或其药学上可接受的衍生物，其中A、B、V、W、X、Y和Z的定义如本文所述；其制药组合物；以及其用途。
• TRIAZOLE COMPOUNDS USEFUL IN THERAPY
  申请人：Pfizer Limited

  公开号：EP1597260B1

  公开（公告）日：2006-12-27
• TREATMENT OF MALE SEXUAL DYSFUNCTION
  申请人：Pfizer Limited

  公开号：EP1656183B1

  公开（公告）日：2007-12-05
• US7442795B2
  申请人：——

  公开号：US7442795B2

  公开（公告）日：2008-10-28